{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:07:09Z","timestamp":1789657629173,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangdong Clinical Research Center for Critical Care Medicine","award":["2020B1111170005"],"award-info":[{"award-number":["2020B1111170005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nafamostat mesylate (NM) is frequently used for continuous renal replacement therapy (CRRT) anticoagulation when clinicians wish to avoid sustained systemic anticoagulation, whereas low-molecular-weight heparin (LMWH) is commonly selected when systemic anticoagulation is considered acceptable. However, direct evidence comparing NM with LMWH in adult intensive care unit (ICU) patients undergoing CRRT remains limited. This study compared filter lifespan, circuit-related failure and safety outcomes between NM and LMWH in a real-world ICU CRRT cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study included adult ICU patients receiving CRRT with NM or LMWH between January 2022 and January 2023. The primary outcome was filter lifespan. In the primary time-to-event analysis, circuit-related filter failure was defined as clotting-related failure or access\/device-related failure, while planned and clinical-event-related terminations were censored. Kaplan\u2013Meier analysis, Cox regression with patient-level cluster-robust standard errors, shared-frailty Cox regression, and propensity score\u2013matched analyses were used to compare filter survival, account for repeated circuits within patients, adjust for CRRT prescription factors, and assess robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 116 patients contributing 344 filters were included: 31 patients with 132 filters in the NM group and 85 patients with 212 filters in the LMWH group. NM-treated patients had greater illness severity and more pronounced coagulation abnormalities. Unadjusted Kaplan\u2013Meier analysis showed shorter filter survival with NM than with LMWH (log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007). However, anticoagulant strategy was not significantly associated with circuit-related filter failure in the primary Cox model (HR 1.41; 95% CI 0.88\u20132.25;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.15), shared-frailty Cox model (HR 1.57; 95% CI 0.85\u20132.90;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.15), extended Cox model (HR 1.16; 95% CI 0.70\u20131.90;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.56), or propensity score\u2013matched analyses. Bleeding events were infrequent, precluding a precise comparison of bleeding risk between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anticoagulant strategy was not significantly associated with circuit-related filter failure after adjustment for measured covariates. Because of substantial baseline differences, residual confounding, and limited statistical precision, these findings should not be interpreted as evidence of comparative efficacy, equivalence, noninferiority, or comparable safety. Larger prospective studies with standardized treatment protocols are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05351-9","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:15:42Z","timestamp":1788797742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nafamostat mesylate versus low-molecular-weight heparin during continuous renal replacement therapy in critically Ill adults: a single-center retrospective cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Xianguo","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4737-7975","authenticated-orcid":false,"given":"Yide","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6402-3389","authenticated-orcid":false,"given":"Yongjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-5510","authenticated-orcid":false,"given":"Liang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"8","key":"5351_CR1","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EA Hoste","year":"2015","unstructured":"Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411\u201323.","journal-title":"Intensive Care Med"},{"key":"5351_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000060097","volume":"132","author":"M Schetz","year":"2001","unstructured":"Schetz M. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol. 2001;132:283\u2013303.","journal-title":"Contrib Nephrol"},{"issue":"1","key":"5351_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13054-023-04519-1","volume":"27","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Liu C, Yang Y, Wang F, Zhang L, Fu P. Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care (London England). 2023;27(1):222.","journal-title":"Crit Care (London England)"},{"issue":"4","key":"5351_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00134-003-1672-8","volume":"29","author":"S Uchino","year":"2003","unstructured":"Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous is not continuous: the incidence and impact of circuit down-time on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med. 2003;29(4):575\u20138.","journal-title":"Intensive Care Med"},{"issue":"4","key":"5351_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/cc5937","volume":"11","author":"M Joannidis","year":"2007","unstructured":"Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care (London England). 2007;11(4):218.","journal-title":"Crit Care (London England)"},{"issue":"9","key":"5351_CR6","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","volume":"33","author":"S Uchino","year":"2007","unstructured":"Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563\u201370.","journal-title":"Intensive Care Med"},{"issue":"2","key":"5351_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00134-005-0044-y","volume":"32","author":"HM Oudemans-van Straaten","year":"2006","unstructured":"Oudemans-van Straaten HM, Wester JPJ, de Pont A, Schetz MRC. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006;32(2):188\u2013202.","journal-title":"Intensive Care Med"},{"issue":"20","key":"5351_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","volume":"332","author":"TE Warkentin","year":"1995","unstructured":"Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330\u20135.","journal-title":"N Engl J Med"},{"issue":"12","key":"5351_CR9","first-page":"Cd012467","volume":"12","author":"H Tsujimoto","year":"2020","unstructured":"Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020;12(12):Cd012467.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1 Suppl","key":"5351_CR10","doi-asserted-by":"publisher","first-page":"s64","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):s64\u201394.","journal-title":"Chest"},{"issue":"3","key":"5351_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/1744-9987.70009","volume":"29","author":"Z Gong","year":"2025","unstructured":"Gong Z, Zhang L, Ma H, SiRi G. Effect of regional citrate anticoagulation vs. low molecular weight heparin anticoagulation in continuous renal replacement therapy for critically ill patients: A retrospective cohort study. Therapeutic apheresis dialysis: official peer-reviewed J Int Soc Apheresis Japanese Soc Apheresis Japanese Soc Dialysis Therapy. 2025;29(3):447\u201358.","journal-title":"Therapeutic apheresis dialysis: official peer-reviewed J Int Soc Apheresis Japanese Soc Apheresis Japanese Soc Dialysis Therapy"},{"issue":"2","key":"5351_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","volume":"37","author":"HM Oudemans-van Straaten","year":"2009","unstructured":"Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37(2):545\u201352.","journal-title":"Crit Care Med"},{"issue":"4","key":"5351_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/03913988211003586","volume":"45","author":"L Li","year":"2022","unstructured":"Li L, Bai M, Zhang W, Zhao L, Yu Y, Sun S. Regional citrate anticoagulation versus low molecular weight heparin for CRRT in hyperlactatemia patients: A retrospective case-control study. Int J Artif Organs. 2022;45(4):343\u201350.","journal-title":"Int J Artif Organs"},{"issue":"1","key":"5351_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1080\/0886022X.2020.1795879","volume":"42","author":"Y Yu","year":"2020","unstructured":"Yu Y, Bai M, Wei Z, Zhao L, Li Y, Ma F, Sun S. Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study. Ren Fail. 2020;42(1):748\u201358.","journal-title":"Ren Fail"},{"issue":"1","key":"5351_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12882-020-02150-8","volume":"21","author":"F Arnold","year":"2020","unstructured":"Arnold F, Westermann L, Rieg S, Neumann-Haefelin E, Biever PM, Walz G, Kalbhenn J, Tanriver Y. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrol. 2020;21(1):486.","journal-title":"BMC Nephrol"},{"issue":"2","key":"5351_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0005-2744(81)90023-1","volume":"661","author":"S Fujii","year":"1981","unstructured":"Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661(2):342\u20135.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"5351_CR17","first-page":"164","volume":"15","author":"Y Hitomi","year":"1985","unstructured":"Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985;15(3):164\u20138.","journal-title":"Haemostasis"},{"issue":"3","key":"5351_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10047-017-0968-3","volume":"20","author":"T Arimura","year":"2017","unstructured":"Arimura T, Abe M, Shiga H, Katayama H, Kaizu K, Oda S. Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013. J Artif organs: official J Japanese Soc Artif Organs. 2017;20(3):244\u201351.","journal-title":"J Artif organs: official J Japanese Soc Artif Organs"},{"issue":"1","key":"5351_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5301\/ijao.5000465","volume":"39","author":"S Makino","year":"2016","unstructured":"Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs. 2016;39(1):16\u201321.","journal-title":"Int J Artif Organs"},{"issue":"10","key":"5351_CR20","doi-asserted-by":"publisher","first-page":"e108737","DOI":"10.1371\/journal.pone.0108737","volume":"9","author":"YK Lee","year":"2014","unstructured":"Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE. 2014;9(10):e108737.","journal-title":"PLoS ONE"},{"issue":"52","key":"5351_CR21","doi-asserted-by":"publisher","first-page":"e2392","DOI":"10.1097\/MD.0000000000002392","volume":"94","author":"JY Choi","year":"2015","unstructured":"Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial. Medicine. 2015;94(52):e2392.","journal-title":"Medicine"},{"issue":"1","key":"5351_CR22","doi-asserted-by":"publisher","first-page":"2580058","DOI":"10.1080\/0886022X.2025.2580058","volume":"47","author":"X Zeng","year":"2025","unstructured":"Zeng X, Cai X, Liao Z, Xiao Y, Wu J, Guan X, Liu Y, Luo L. Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety. Ren Fail. 2025;47(1):2580058.","journal-title":"Ren Fail"},{"issue":"3","key":"5351_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/sdi.12946","volume":"34","author":"W Zhang","year":"2021","unstructured":"Zhang W, Bai M, Yu Y, Chen X, Zhao L, Chen X. Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: A systematic review and meta-analysis. Semin Dial. 2021;34(3):196\u2013208.","journal-title":"Semin Dial"},{"issue":"10","key":"5351_CR24","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.","journal-title":"PLoS Med"},{"key":"5351_CR25","unstructured":"National Health Commission of the People\u2019s Republic of China: Standard Operating Procedures for Blood Purification. (2021 edition). In. Beijing. 2021."},{"issue":"9","key":"5351_CR26","first-page":"Cd013330","volume":"9","author":"Y Tsujimoto","year":"2021","unstructured":"Tsujimoto Y, Miki S, Shimada H, Tsujimoto H, Yasuda H, Kataoka Y, Fujii T. Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2021;9(9):Cd013330.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"5351_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13054-022-03910-8","volume":"26","author":"Y Tsujimoto","year":"2022","unstructured":"Tsujimoto Y, Fujii T. How to Prolong Filter Life During Continuous Renal Replacement Therapy? Crit Care (London England). 2022;26(1):62.","journal-title":"Crit Care (London England)"},{"issue":"1","key":"5351_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12882-017-0445-5","volume":"18","author":"M Brain","year":"2017","unstructured":"Brain M, Winson E, Roodenburg O, McNeil J. Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):69.","journal-title":"BMC Nephrol"},{"issue":"1","key":"5351_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12882-023-03060-1","volume":"24","author":"S Kameda","year":"2023","unstructured":"Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, Uezono S. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC Nephrol. 2023;24(1):12.","journal-title":"BMC Nephrol"},{"issue":"1","key":"5351_CR30","first-page":"302","volume":"12","author":"W Wang","year":"2026","unstructured":"Wang W, Zhao J, Zhang X, Wang L, Zhang X, Zhang Z, Qian S. Comparison of Anticoagulant Effects of Nafamostat Mesilate and Heparin in Continuous Renal Replacement Therapy for Patients with High Bleeding Risk: A Meta-Analysis Systemic Review. Kidney Dis (Basel Switzerland). 2026;12(1):302\u201317.","journal-title":"Kidney Dis (Basel Switzerland)"},{"issue":"1","key":"5351_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-025-05813-w","volume":"30","author":"C Liu","year":"2025","unstructured":"Liu C, Yang Y, Ren J, Huang Y, Wei W, Li X, Wang F, Tang X, Fu P, Zhang L, et al. Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis. Crit Care (London England). 2025;30(1):43.","journal-title":"Crit Care (London England)"},{"issue":"4","key":"5351_CR32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/01.mat.0000227733.03278.5f","volume":"52","author":"AC de Pont","year":"2006","unstructured":"de Pont AC, Bouman CS, Bakhtiari K, Schaap MC, Nieuwland R, Sturk A, Hutten BA, de Jonge E, Vroom MB, Meijers JC, et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO J (American Soc Artif Intern Organs: 1992). 2006;52(4):416\u201322.","journal-title":"ASAIO J (American Soc Artif Intern Organs: 1992)"},{"issue":"11","key":"5351_CR33","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2215\/CJN.02410220","volume":"15","author":"P Hatamizadeh","year":"2020","unstructured":"Hatamizadeh P, Tolwani A, Palevsky P. Revisiting Filtration Fraction as an Index of the Risk of Hemofilter Clotting in Continuous Venovenous Hemofiltration. Clin J Am Soc Nephrology: CJASN. 2020;15(11):1660\u20132.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"1","key":"5351_CR34","doi-asserted-by":"publisher","first-page":"sfaf360","DOI":"10.1093\/ckj\/sfaf360","volume":"19","author":"C Liu","year":"2026","unstructured":"Liu C, Fan S, Yang L, Wei W, Huang Y, Chen Z, Bu Q, Wang F, Tang X, Yang Y, et al. Higher blood flow rates in anticoagulation-free CRRT improve circuit survival and clinical outcome. Clin kidney J. 2026;19(1):sfaf360.","journal-title":"Clin kidney J"},{"issue":"10","key":"5351_CR35","doi-asserted-by":"publisher","first-page":"e1018","DOI":"10.1097\/CCM.0000000000002568","volume":"45","author":"N Fealy","year":"2017","unstructured":"Fealy N, Aitken L, du Toit E, Lo S, Baldwin I. Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial. Crit Care Med. 2017;45(10):e1018\u201325.","journal-title":"Crit Care Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05351-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:21:33Z","timestamp":1789654893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05351-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5351"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05351-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines and regulations. The study was approved by the Institutional Review Board of the First Affiliated Hospital of Sun Yat-sen University (Approval No. [2024]311). The requirement for informed consent was waived because the study involved retrospective review of existing medical records without direct patient contact or additional study-related procedures.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"546"}}